134 related articles for article (PubMed ID: 20202110)
21. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients.
Cesaro S; Giacchino M; Locatelli F; Spiller M; Buldini B; Castellini C; Caselli D; Giraldi E; Tucci F; Tridello G; Rossi MR; Castagnola E
BMC Infect Dis; 2007 Apr; 7():28. PubMed ID: 17442100
[TBL] [Abstract][Full Text] [Related]
22. Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry.
Maertens J; Egerer G; Shin WS; Reichert D; Stek M; Chandwani S; Shivaprakash M; Viscoli C;
BMC Infect Dis; 2010 Jun; 10():182. PubMed ID: 20569436
[TBL] [Abstract][Full Text] [Related]
23. Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients.
Glasmacher A; Cornely OA; Orlopp K; Reuter S; Blaschke S; Eichel M; Silling G; Simons B; Egerer G; Siemann M; Florek M; Schnitzler R; Ebeling P; Ritter J; Reinel H; Schütt P; Fischer H; Hahn C; Just-Nuebling G
J Antimicrob Chemother; 2006 Jan; 57(1):127-34. PubMed ID: 16308418
[TBL] [Abstract][Full Text] [Related]
24. Phase II dose escalation study of caspofungin for invasive Aspergillosis.
Cornely OA; Vehreschild JJ; Vehreschild MJ; Würthwein G; Arenz D; Schwartz S; Heussel CP; Silling G; Mahne M; Franklin J; Harnischmacher U; Wilkens A; Farowski F; Karthaus M; Lehrnbecher T; Ullmann AJ; Hallek M; Groll AH
Antimicrob Agents Chemother; 2011 Dec; 55(12):5798-803. PubMed ID: 21911573
[TBL] [Abstract][Full Text] [Related]
25. Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients.
Lellek H; Waldenmaier D; Dahlke J; Ayuk FA; Wolschke C; Kröger N; Zander AR
Mycoses; 2011 Jan; 54 Suppl 1():39-44. PubMed ID: 21126271
[TBL] [Abstract][Full Text] [Related]
26. Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections.
Heinz WJ; Buchheidt D; Ullmann AJ
Mycoses; 2016 Aug; 59(8):480-93. PubMed ID: 27324802
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
Maertens J; Raad I; Petrikkos G; Boogaerts M; Selleslag D; Petersen FB; Sable CA; Kartsonis NA; Ngai A; Taylor A; Patterson TF; Denning DW; Walsh TJ;
Clin Infect Dis; 2004 Dec; 39(11):1563-71. PubMed ID: 15578352
[TBL] [Abstract][Full Text] [Related]
28. Comedication of caspofungin acetate and cyclosporine A after allogeneic haematopoietic stem cell transplantation leads to negligible hepatotoxicity.
Christopeit M; Eikam M; Behre G
Mycoses; 2008; 51 Suppl 1():19-24. PubMed ID: 18471157
[TBL] [Abstract][Full Text] [Related]
29. Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States.
Kim A; Nicolau DP; Kuti JL
Mycoses; 2011 Sep; 54(5):e301-12. PubMed ID: 20557463
[TBL] [Abstract][Full Text] [Related]
30. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation.
Groetzner J; Kaczmarek I; Wittwer T; Strauch J; Meiser B; Wahlers T; Daebritz S; Reichart B
J Heart Lung Transplant; 2008 Jan; 27(1):1-6. PubMed ID: 18187079
[TBL] [Abstract][Full Text] [Related]
31. Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study).
Jarque I; Tormo M; Bello JL; Rovira M; Batlle M; Julià A; Tabares S; Rivas C; Fernández-Sevilla A; García-Boyero R; Debén G; González-Campos J; Capote FJ; Sanz MA;
Med Mycol; 2013 Feb; 51(2):150-4. PubMed ID: 22712457
[TBL] [Abstract][Full Text] [Related]
32. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.
Aliff TB; Maslak PG; Jurcic JG; Heaney ML; Cathcart KN; Sepkowitz KA; Weiss MA
Cancer; 2003 Feb; 97(4):1025-32. PubMed ID: 12569602
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.
Kontoyiannis DP; Hachem R; Lewis RE; Rivero GA; Torres HA; Thornby J; Champlin R; Kantarjian H; Bodey GP; Raad II
Cancer; 2003 Jul; 98(2):292-9. PubMed ID: 12872348
[TBL] [Abstract][Full Text] [Related]
34. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis.
Kontoyiannis DP; Ratanatharathorn V; Young JA; Raymond J; Laverdière M; Denning DW; Patterson TF; Facklam D; Kovanda L; Arnold L; Lau W; Buell D; Marr KA
Transpl Infect Dis; 2009 Feb; 11(1):89-93. PubMed ID: 18983417
[TBL] [Abstract][Full Text] [Related]
35. Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey.
Groll AH; Attarbaschi A; Schuster FR; Herzog N; Grigull L; Dworzak MN; Beutel K; Laws HJ; Lehrnbecher T
J Antimicrob Chemother; 2006 Mar; 57(3):527-35. PubMed ID: 16431856
[TBL] [Abstract][Full Text] [Related]
36. Caspofungin.
Parakh A; Dubey AP; Samanta D
Indian Pediatr; 2008 Nov; 45(11):905-10. PubMed ID: 19029563
[TBL] [Abstract][Full Text] [Related]
37. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium.
Selleslag D; Vogelaers D; Marbaix S
Acta Clin Belg; 2009; 64(5):393-8. PubMed ID: 19999386
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of caspofungin in obese patients.
Ryan DM; Lupinacci RJ; Kartsonis NA
Med Mycol; 2011 Oct; 49(7):748-54. PubMed ID: 21466264
[TBL] [Abstract][Full Text] [Related]
39. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.
Maertens JA; Madero L; Reilly AF; Lehrnbecher T; Groll AH; Jafri HS; Green M; Nania JJ; Bourque MR; Wise BA; Strohmaier KM; Taylor AF; Kartsonis NA; Chow JW; Arndt CA; DePauw BE; Walsh TJ;
Pediatr Infect Dis J; 2010 May; 29(5):415-20. PubMed ID: 20431381
[TBL] [Abstract][Full Text] [Related]
40. Caspofungin Increases Fungal Chitin and Eosinophil and γδ T Cell-Dependent Pathology in Invasive Aspergillosis.
Amarsaikhan N; Sands EM; Shah A; Abdolrasouli A; Reed A; Slaven JE; Armstrong-James D; Templeton SP
J Immunol; 2017 Jul; 199(2):624-632. PubMed ID: 28566368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
